NetworkNewsBreaks

FridayMay 15, 2020 1:46 pm

NetworkNewsBreaks – Gevo, Inc. (NASDAQ: GEVO) Reports Financial Results for Q1 2020

Gevo (NASDAQ: GEVO) this week announced financial results for the first quarter of 2020 and recent corporate highlights. “We are focused on building our business for the long run. We continue to make and sell renewable premium gasoline and jet fuel. We’ve cut expenses, cut the burn. We are pleased to be working with Citigroup on our project financings. We are moving forward, and look forward to completing them,” Gevo’s Chief Executive Officer, Dr. Patrick R. Gruber, said in the news release. “Building these projects off balance sheet, where we take the role of developer, licensor and operator, seems to…

Continue Reading

FridayMay 15, 2020 1:44 pm

NetworkNewsBreaks – Ceapro Inc. (TSX-V: CZO) (OTCQX: CRPOF) Releases Results and Highlights for Q4 and Full Year 2019

Ceapro Inc. (TSX-V: CZO) (OTCQX: CRPOF), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, recently announced operational highlights and financial results for the fourth quarter and full year ended December 31, 2019. “Over the course of 2019, in addition to having delivered another solid year with our base business serving the cosmeceutical sector, Ceapro took the strategic steps to maintain our vision to transition to a new business model from a contract manufacturer to a biopharmaceutical company offering innovative products and delivery systems to the nutraceutical and biopharmaceuticals sectors. To…

Continue Reading

FridayMay 15, 2020 1:12 pm

NetworkNewsBreaks – Cumulus Media Inc. (NASDAQ: CMLS) Reports Q1 2020 Operating Results

Cumulus Media (NASDAQ: CMLS) (the "Company" or "CUMULUS MEDIA") today announced operating results for the three months ended March 31, 2020. “Regardless of the challenge, the Cumulus team has focused acutely on what matters most, moved decisively where it will make a difference, and executed every effort efficiently and with an eye toward creating value,” CUMULUS MEDIA President and CEO Mary G. Berner stated in the news release. “Our reaction to this unprecedented COVID-19 crisis has been no different. We entered March with strong financial performance, a favorable capital structure and significant liquidity, and we’ve taken swift actions that we…

Continue Reading

FridayMay 15, 2020 12:54 pm

NetworkNewsBreaks – PDS Biotechnology Corporation (NASDAQ: PDSB) Announces Q1 2020 Financial Results, Provides Business Update

PDS Biotechnology (NASDAQ: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune(R) T-cell activating technology, on Wednesday announced its financial results for the first quarter ended March 31, 2020 and provided a business update. Among the highlights, the Company announced initiation of novel vaccine development programs for COVID-19 and universal influenza. “We have continued to leverage the versatility and potency of our Versamune(R) platform, as we expand our development program to include vaccines to protect against infectious diseases such as COVID-19 and influenza,” PDS Biotech President and CEO, Dr. Frank…

Continue Reading

FridayMay 15, 2020 12:30 pm

NetworkNewsBreaks – Ely Gold Royalties Inc. (TSX.V: ELY) and Co-Lead Agents Upsize Brokered Private Placement

Ely Gold Royalties (TSX.V: ELY) recently announced that, due to investor demand in connection with its previously announced marketed private placement, the company and a syndicate of agents led by Clarus Securities Inc. and Mackie Research Capital Corp. (the "co-lead agents") have agreed to increase the size of the previously announced offering to C$15,000,000 at a price of C$0.80 per unit. According to the update, the company will additionally grant the co-lead agents an over-allotment option to sell an additional 2,812,500 units, exercisable in whole or in any part, for a period of 30 days from and including the closing…

Continue Reading

FridayMay 15, 2020 12:25 pm

NetworkNewsBreaks – Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) Featured in Channelchek Research Report, Releases Q1 2020 Financial Results

Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) was featured in an April Research Report published by Channelchek. The report, titled, “Two Breakthrough Medical Technologies for Cardiovascular Markets,” details two Neovasc products, including Tiara for the transcatheter treatment of mitral valve disease and the Neovasc Reducer for the treatment of refractory angina. The report reads, “Neovasc is seeking FDA approval to commercialize the Reducer for the treatment of refractory angina in the United States. Patients suffering from refractory angina, a debilitating disease characterized by chronic chest pain, do not have any effective therapeutic options. The Reducer, commercially available in Europe, but not…

Continue Reading

FridayMay 15, 2020 11:25 am

NetworkNewsBreaks – Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX) Joins AWARD Consortium for Development of Autonomous Heavy-Duty Vehicles

Foresight Autonomous Holdings (NASDAQ: FRSX) (TASE: FRSX), an innovator in automotive vision systems, today announced that it has joined the All Weather Autonomous Real logistics operations and Demonstrations (“AWARD”) consortium. According to the update, the AWARD consortium submitted an application to the European Commission (“Horizon 2020”) to win funding for a large-scale project aimed at bringing disruptive change to the trucking industry, fleet operators and the entire logistics sector. The grant is expected to total 20 million Euro, of which Foresight is expected to receive approximately one million USD. The project will be rolled out in 2021 for a period…

Continue Reading

FridayMay 15, 2020 11:19 am

NetworkNewsBreaks – Supreme Cannabis Company, Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) Announces Financial Results for Q3 2020

Supreme Cannabis Company (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) today announced its financial and operating results for the three and nine months ended March 31, 2020. “In our third quarter, we made significant progress towards our goal of improving the company's cost structure while creating opportunities for near-term revenue growth. Although much of this progress is not reflected in our Q3 financial results, we did begin to see the early impacts of our rightsizing and revenue generation efforts,” Colin Moore, who recently served as interim president and CEO of Supreme Cannabis, stated in the news release. “Excluding restructuring charges, we…

Continue Reading

FridayMay 15, 2020 10:24 am

NetworkNewsBreaks – VIVO Cannabis Inc. (TSX: VIVO) (OTCQX: VVCIF) Announces Results for Q1 2020

VIVO Cannabis (TSX: VIVO) (OTCQX: VVCIF) on Thursday released its first quarter 2020 financial and operating results. Among the highlights, the company reported an increase in net revenue to $8.2 million. “Our positive first quarter 2020 results were fueled by a net revenue increase of 24% compared with the previous quarter,” VIVO CEO Barry Fishman said in the news release. “Several of our Canna Farms(TM) and Fireside(TM) cannabis 2.0 products are showing strong momentum, and the VIVO team continued to execute well on plans related to our four strategic priorities, despite COVID-19 related challenges. In April, we started planting in…

Continue Reading

FridayMay 15, 2020 10:18 am

NetworkNewsBreaks – Grey Cloak Tech Inc. (GRCK) Introduces Proprietary Ketogenic Solution for Brain Health – F4T(TM)

Grey Cloak Tech (OTC: GRCK), engaged in proprietary development of natural plant-based formulations, sales and distribution of cardiovascular and neuro products, on Thursday introduced its proprietary F4T(TM) formulation, a natural ketogenic solution clinically proven to deliver metabolic energy to the brain to improve attention, cognition, memory and analytical and executive function. According to the update, F4T(TM) was developed by Grey Cloak Tech’s Ultimate Brain Nutrients (“UBN”) subsidiary and is the end-result of more than 40 iterations and several years of stringent development. “I am excited to announce our proprietary F4T(TM) formulation, which will be the foundation for studies, products and…

Continue Reading